Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capivasertib + olaparib + durvalumab
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of capivasertib (AZD5363), olaparib, and durvalumab. Capivasertib is a pan-AKT inhibitor that targets all AKT isoforms with high potency. Olaparib is a PARP inhibitor that blocks DNA repair mechanisms. Durvalumab is a PD-L1 inhibitor that works as an immune checkpoint inhibitor. This triple combination aims to simultaneously target multiple cancer pathways: AKT signaling, DNA damage repair, and immune evasion.
- Brand names
- TruqapLynparzaImfinzi
- Other names
- AZD5363 + olaparib + durvalumabcapivasertib + olaparib + durvalumab
02
Targets
AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CD274 (Programmed cell death protein 1 ligand 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on capivasertib + olaparib + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capivasertib + olaparib + durvalumab.